Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. - Wikidata - awgldk - TriplyDB

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

http://www.wikidata.org/entity/Q34023973

about

Interstitial ultrasound ablation of vertebral and paraspinal tumours: parametric and patient-specific simulations.Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling.PET/CT in Oncology: Current Status and Perspectives.Clinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy.Positron Emission Tomography (PET) in Oncology Successful radiopeptide targeting of metastatic anaplastic meningioma: case report FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer.Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer.Bony metastases: assessing response to therapy with whole-body diffusion MRI.Developing imaging strategies for castration resistant prostate cancer Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer.Evaluation of cancer treatment in the abdomen: Trends and advances.Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer Multimodality imaging of osseous involvement In haematological malignancies Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.RANKL: A promising circulating marker for bone metastasis response May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.Future directions for monitoring treatment responses in breast cancer.Usefulness of dynamic contrast-enhanced magnetic resonance imaging for predicting treatment response to vinorelbine-cisplatin with or without recombinant human endostatin in bone metastasis of non-small cell lung cancer.Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives.Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers International consensus on use of focused ultrasound for painful bone metastases: Current status and future directions.Focused ultrasound for treatment of bone tumours.Bone metastases in lung cancer. Potential novel approaches to therapy.(99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials.Computed Tomography Evaluation of Density Following Stereotactic Body Radiation Therapy of Nonspine Bone Metastases.Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.[18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells.Outcomes of Spatially Fractionated Radiotherapy (GRID) for Bulky Soft Tissue Sarcomas in a Large Animal Model.Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Electrochemotherapy in the Treatment of Bone Metastases: A Phase II Trial Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial.Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy.Therapy monitoring of skeletal metastases with whole-body diffusion MRI.Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone.Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay.

P2860

Q30395233-A6A43A1E-BA0D-491F-9C27-FE8693EED178 Q33589156-3BF84272-181C-46F5-BA26-687D684BFD38 Q33665109-C3E4F0A6-8D2C-4F9B-A038-D9FA9022CE4A Q34305928-7BF7D1D1-C6A3-49E1-8A90-C0A2D9E244A0 Q34774840-D3012AF5-2509-41B7-ADA4-6157893465B1 Q35206154-A80161B7-489E-43CD-8236-64EE594AB5CC Q35584721-D66C3626-6669-4FBD-AEFF-41C19DD9A0E6 Q35598954-F339CCFC-97BB-421B-AEA6-D458DCB8B5B3 Q35697593-2CBBFE4E-0096-4C84-A23D-0268BC3A576F Q36152211-7B1F4D42-8400-4D98-8036-00DDBBCB941C Q36540092-A51969C5-3EFE-4253-8029-010D72D9D82A Q36550767-19F4C447-7C23-4B26-93F5-F764356D3943 Q36832118-6C68A46B-AE2E-4852-BA05-61DF8AD843B5 Q37127044-555C4FEF-23F8-456B-8BDC-82F8343937AC Q37178919-C2353A91-0825-42F0-A935-303B5518769D Q37201458-34E883B6-DF05-41E4-AFB2-70E33C4A7341 Q37288243-09A5081D-8E84-42FE-8A93-13CCCF4D3273 Q37402627-3516997C-E8EF-4DBA-841B-3340968F0CA4 Q37435201-6614A995-7C0E-4AF8-8B4D-A0E89CD0DD74 Q37545124-4549AAB8-403F-4BD9-8A4C-95F4C9D12DA3 Q37729968-F3763C35-3526-4E9F-B55D-32C9956FC2AD Q37902873-6A105299-673B-4A87-81E0-A28951EE9E14 Q38354147-50C3E97B-BAA7-483D-9C82-FBACA964DD0D Q38397204-19A4ACD8-013E-4CA3-992A-EB06C7AC4B30 Q38541387-40D64C42-552A-4EA3-95C6-5CBA7B6CA4DC Q38566895-8D1B5F48-D475-4631-BCCE-EB7D4386C9CE Q38583275-E1463345-3A10-4033-88C7-6E43220C1CD0 Q38766102-647FE90C-CBD8-4370-87DE-1DDD7ED63CC3 Q38939387-D2E0A9FF-6BDB-48BE-BEC1-EFFD82A4C7C4 Q38974740-2CE8616F-6DB1-4CE1-8818-BA9A49BE4BC5 Q39189394-7BCD1F07-D35A-4042-8718-C04A0B6E263A Q39401628-C49B3ED1-4F4A-44E6-80DF-7ECC9F936801 Q41850540-FCAA71E4-A8B2-41C8-9092-AB018D10B867 Q42362967-0800A7EF-70EC-4EBA-B773-1F4009A06B67 Q42586178-28415FD5-460D-4D1F-AB0D-D3D3A078A80B Q43822307-DBC0BA69-B1E7-4656-A9EC-2E736A576CAF Q51114179-91EE3B1D-2160-475D-BDFD-C90985CB01F7 Q51838938-D3960F6E-3223-41F3-9417-4AF8954508D7 Q52888052-F9ADC268-A786-4699-AB49-B6CF73D66257 Q52964699-0CB223C1-972E-4B14-AB36-0174BFDB687D

P2860

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

http://www.wikidata.org/entity/Q34023973

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

@ast

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

@en

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

@nl

type

label

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

@ast

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

@en

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

@nl

prefLabel

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

@ast

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

@en

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

@nl

P1433

Q34023973-229BD4AA-DF05-442C-AEB9-344BE242A5C2

P1476

Q34023973-16912EBE-F531-44F2-9E88-E5BA7DC27C6E

P2093

Q34023973-1B115929-DC5C-455A-A659-54D4B7FFC84C

Q34023973-3AA2668B-12E1-478F-A160-E7D956F4F23B

Q34023973-D0C28CF4-8FE2-4B4D-88E1-01A50B1E9D29

Q34023973-D0E3BEB1-0ADF-4EFA-B031-A14BD89B4011

P2860

Q34023973-0C458229-F5CC-4C91-8D32-C11B12C4E104

Q34023973-0D08C485-28A4-4DAB-8C47-7A182A6B1915

Q34023973-1323EFC0-E650-4F37-AA3B-9FFD60B9657D

Q34023973-16316F4E-481A-4DBB-9436-ADA68507C4D3

Q34023973-1F81D6D5-1EBD-4CE2-9F13-16811567BA4E

Q34023973-2C2E9653-1EB8-46D4-BD75-E42629B9D3DC

Q34023973-3007F112-1511-40F6-AF4E-D3B9626CF6EF

Q34023973-310AAC52-5D78-4BD2-B236-E71046F31D42

Q34023973-31644BAA-667C-4618-AE76-5B944E75291C

Q34023973-31D9A78A-DE71-46C9-A4BF-A02CF4117A0C

P304

Q34023973-D88C0FB5-3DFE-42A7-A9A8-44DD4724F6BB

P31

Q34023973-76A9727A-0B99-438D-8198-470FB1E4DD54

P356

Q34023973-88F0175A-4B06-49AF-82B7-6ACDCCCE87F4

P478

Q34023973-724D9691-DD43-48E2-8A55-573076C2893F

P577

Q34023973-FCF2C783-9D21-494F-B00E-D1265EA1437E

P698

Q34023973-80370BE8-4316-49F8-8128-F4EBF7F2684A

P932

Q34023973-7A1CD174-E277-446A-89F3-AEBC8A288DEF

P356

P1433

Journal of Cancer

P1476

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

@en

P2093

Colleen M Costelloe

http://www.w3.org/2001/XMLSchema#string

Hubert H Chuang

http://www.w3.org/2001/XMLSchema#string

John E Madewell

http://www.w3.org/2001/XMLSchema#string

Naoto T Ueno

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography

Reporting results of cancer treatment

Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer.

Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Metastases in carcinoma; analysis of 1000 autopsied cases.

Clinical features of metastatic bone disease and risk of skeletal morbidity.

MRI and CT evaluation of primary bone and soft-tissue tumors.

P304

80-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.1.80

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20842228

http://www.w3.org/2001/XMLSchema#string

P932

2938069

http://www.w3.org/2001/XMLSchema#string